Bioniz was founded on an idea that small peptides could be rationally designed to selectively inhibit functionally redundant cytokines by targeting receptors that are shared within a family of cytokines. Many diseases are driven by the collective dysregulation of multiple cytokines and are, therefore, inherently beyond the reach of current therapies, which lack either the breadth or the specificity to address this more complex pathology.
Our M3 Technology platform dissects the evolutionary biological concept of “redundancy” that exists within families of cytokines, which is defined as several cytokines sharing a common receptor and therefore exhibiting redundant functionality. It has become increasingly understood that members of a cytokine family possess overlapping responsibilities to ensure the vital maintenance of an immune response in the event the primary family member is either disrupted or dysregulated.
Our core value proposition is to selectively inhibit cytokine members within a family while allowing non-blocked members to continue providing immune function. Our breakthrough technology has allowed us to generate first-in-class peptides to achieve this goal. We rationally design our peptides to occupy select binding pockets on the common receptor that are highly specific for targeted members of the cytokine family. By inhibiting selected cytokines while leaving redundant family members free to bind to the common receptor, we can broaden the degree of cytokine blockade that is achievable while normal systemic immune functionality is preserved.
BNZ-1 is our lead investigational drug. It is a peptide that targets the shared receptor (γc) in the IL-2 family of cytokines that is utilized by all six family members (IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21). BNZ-1 selectively inhibits IL-2, IL-9, and IL-15, but not the other cytokines in this family. BNZ-1 blocks the excessive activity of IL-2, IL-9 and IL-15 in diseases where these cytokines are implicated. The other undisrupted cytokines, IL-4, IL-7, and IL-21, protect the normal immune balance through their redundant functions.
Bioniz’s strategy is multifold:
Develop and commercialize our two novel multi-cytokine inhibitors, BNZ-1 and BNZ-2, in multiple indications where disease etiology is linked to an overexpression of the different combination of cytokines that these two first-in-class peptides are designed to inhibit. This year, the Company plans to enter a late-stage clinical trial with the lead therapeutic program, BNZ-1 for cutaneous T-cell lymphoma (CTCL), and a Phase 2 clinical study of BNZ-1 for alopecia areata.
Advance the development of oral BNZ-3 for the treatment of inflammatory diseases of the gut and pave the way for developing other orally bioavailable and selective multi-cytokine inhibitors for a variety of immune diseases.
Further identify disease pathologies driven by multi-cytokine dysregulation and develop customized multi-cytokine targeting peptides for each disease.
Power our M3 platform technology to expand to other families of cytokines where multiple cytokines share a common receptor, including but not limited to the IL-6 and IL-17 families.
Optimize our cytokine modulation technology to enable design and development of multi-cytokine activators for treatment of cancer and as vaccine adjuvants.
We are a pioneering biopharmaceutical company dedicated to the betterment of patients’ lives. We value bold thinking and the pursuit of new avenues of science to solve unmet medical needs. Our team is a group of engaged, talented, compassionate, and dedicated scientists and experienced pharmaceutical professionals who have come together in pursuit of the potential of our unique science.
If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law,
and you wish to discuss potential accommodations related to using this website, please contact our Accessibility Manager by filling out a contact form.